 |
| |
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments analyses the world vaccine market. This report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Hepatitis B vaccines, Pneumococcal vaccines, Cervical Cancer vaccines etc. are there in the report. Forecasts for the future market size of vaccine for diseases like Malaria, Ebola, Tuberculosis (TB), Japanese Encephalitis, West Nile, Typhoid etc. which are yet to be launched in the market have also been included in the report. The report also forecasts the sales of the key vaccines brands like Gardasil, Fluzone/Vaxigrip/Mutagrip, Prevnar, RotaTeq and Rotarix. Major companies' vaccines sales data for the year 2007 and 2008 are also provided. Market Overview
The vaccines landscape is very different now compared to a few years ago. With increasing public awareness about preventive healthcare and increased spending by governments for the same has once again put spotlight on the vaccines. Quality of life is expected to increase markedly with introduction of newer vaccines covering more and more diseases. Due to this vaccines, which were perceived as low margin business before, have now emerged as one of the most lucrative segments in the pharmaceutical industry. Moreover with the success of a number of blockbuster products, the market place has changed dramatically. Pharma major's today look upon vaccines as a driver for their future growth.
Vaccines have become big business for pharmaceutical giants like GlaxoSmithKline, sanofi pasteur and Merck & Co.. For e.g. GSK Bio, GSK's vaccines arm, accounted for 8.4 percent of GSK's pharmaceutical turnover in 2006. And it is expected that by 2012 companies like GSK, Sanofi-aventis, Merck & Co., and Wyeth vaccines arm will fetch them more than 10 percent of sales from vaccine as a percentage of overall pharma sales.
Basic pediatrics share is declining as most of the vaccines in this sector are either off patent or newer and more effective vaccines have replaced them. Proprietary pediatrics and cancer pediatrics will define the future growth going forward. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to cross the US$ 2 Billion annual sales in 2007.
With the growth in international travel vaccine market of adult/travel sector is also going to grow further. Malaria vaccines, Typhoid Vaccines and Japanese Encephalitis Vaccines are expected to grow further in the market. Malaria vaccine which is expected to launch in 2010 or 2011, is forecasted to be worth US$ 419 Million market by 2025. Typhoid vaccine market for travelers is expected to grow with a CAGR of 4 percent from 2003 to 2014.
Ongoing spate of mergers and accquisition in pharma sector its effect and causes on the overall industry. Such as Pfizer taking over Wyeth would cement Pfizer's position as the world's leading drugmaker. Geographic segment wise China and India vaccine market will grow considerably in future and Japanese vaccine market has also started to open up further from regulatory and political barriers. Overall the worldwide vaccine market has registered revenue of US$ 21 Billion in 2008.
Report Forecast
• Worldwide Vaccine Market
• Influenza Market
• Adult/Travel Market
• Proprietary Pediatrics/Adolescent Market
• Enhanced Pediatrics Market
• Basic Pediatrics Market
• Major Vaccines Market (For complete list see heading no. 4 below in table of contents)
• Major Geographic Vaccine Markets
• Sales Forecast for Key Vaccine Brands (Cervarix, RotaTeq, Flu, Zostavax, ProQuad, Infanrix (DTP), Menactra, Rotarix, Gardasil, Prevnar, Fluzone/Vaxigrip/Mutagrip, 13-Valent Pneumococcal, Synflorix, Imvamune, H5N1 Influenza Vaccine, Hepatitis B vaccine).
Research Highlights
• M&A by big pharma like Pfizer and Merck and its effect in terms of consolidation in pharma industry.
• Collectively Europe & Asia Pacific accounts for the 60 percent of the Hepatitis B vaccine market.
• Public market share of malaria vaccine revenue increases from 43 percent in 2015 to 77 percent in 2025.
• Japanese encephalitis vaccine market is expected to cross the figure of US$ 400 Million by 2012.
• By 2015 it is expected that Cervical Cancer patients will be 320 Thousand worldwide.
• India and China vaccine market is expected to grow with a CAGR of 16 and 17.8 percent respectively from 2006 to 2013.
• Vaccines like Infanrix (DTP) of GSK and the flu vaccine of Sanofi-Pasteur will have a market of more than US$1 Billion by 2010.
• Despite global slowdown vaccine sale of all major companies such as Merck, GSK, Sanofi Aventis has been increased in 2008 compared to 2007.
• 14 different vaccines have been analyzed in the report (for details refer heading no. 4 below in table of contents).
Data Sources
The information and data in this report has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments: http://www.companiesandmarkets.com/r.ashx?id=rX8FhIE6y167915
|
—
